Table 2.
Comparison of age- and sex-stratified cumulative incidence to incidence at 2.7 years follow-up of human papillomavirus (HPV) vaccine initiation among childhood and adolescent and young adult (AYA) cancer survivors after therapy
Age at eligibility | Cumulative incidence | Incidence at 2.7 years follow-up |
---|---|---|
Female | ||
11–17 years | 48.1% | 29.3% |
18–26 years | 6.2% | 5.3% |
Male | ||
11–17 years | 29.2% | 13.7% |
18–26 years | 2.0% | 1.1% |